160 related articles for article (PubMed ID: 9353591)
1. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
Krucher NA; Meijer L; Roberts MH
Cell Mol Neurobiol; 1997 Oct; 17(5):495-507. PubMed ID: 9353591
[TBL] [Abstract][Full Text] [Related]
2. Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia.
Sankrithi N; Eskin A
J Neurochem; 1999 Feb; 72(2):605-13. PubMed ID: 9930732
[TBL] [Abstract][Full Text] [Related]
3. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity.
Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E
Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096
[TBL] [Abstract][Full Text] [Related]
4. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
6. Stopping the circadian pacemaker with inhibitors of protein synthesis.
Khalsa SB; Whitmore D; Block GD
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10862-6. PubMed ID: 1438290
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
8. A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity.
Iseki H; Ko TC; Xue XY; Seapan A; Townsend CM
J Gastrointest Surg; 1998; 2(1):36-43. PubMed ID: 9841966
[TBL] [Abstract][Full Text] [Related]
9. The effect of the cyclin-dependent kinase inhibitor olomoucine on cell cycle kinetics.
Schutte B; Nieland L; van Engeland M; Henfling ME; Meijer L; Ramaekers FC
Exp Cell Res; 1997 Oct; 236(1):4-15. PubMed ID: 9344580
[TBL] [Abstract][Full Text] [Related]
10. A novel mechanism for the control of circadian clock period by light.
Page TL
J Biol Rhythms; 2000 Apr; 15(2):155-62. PubMed ID: 10762033
[TBL] [Abstract][Full Text] [Related]
11. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM
Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267
[TBL] [Abstract][Full Text] [Related]
12. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
13. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
14. Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons.
Monaco EA; Beaman-Hall CM; Mathur A; Vallano ML
Biochem Pharmacol; 2004 May; 67(10):1947-64. PubMed ID: 15130771
[TBL] [Abstract][Full Text] [Related]
15. Evidence for a central role of transcription in the timing mechanism of a circadian clock.
Khalsa SB; Whitmore D; Bogart B; Block GD
Am J Physiol; 1996 Nov; 271(5 Pt 1):C1646-51. PubMed ID: 8944648
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of C2 alkynylated purines, a new family of potent inhibitors of cyclin-dependent kinases.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L
Bioorg Med Chem Lett; 1998 Apr; 8(7):793-8. PubMed ID: 9871543
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
19. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
20. The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.
Peñuelas S; Alemany C; Noé V; Ciudad CJ
Eur J Biochem; 2003 Dec; 270(24):4809-22. PubMed ID: 14653808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
